Clinical stage pharmaceutical company Alitair Pharmaceuticals is currently presenting at the ongoing Cavendish Global Health Impact Forum in Cleveland, Ohio, which kicked off Sunday, October 25, and concludes on October 28th. The forum is co-presented by the Cleveland Clinic and aims to facilitate the development and implementation of family offices and organizations’ pro-social impact investments, awarding of grants, and philanthropic efforts in the health and life sciences. Alitair was invited to give a presentation on its portfolio of product candidates for bronchiectasis, which is currently classified as an orphan respiratory disease.
Bronchiectasis is a pulmonary disease that causes permanent enlargement of the lung airways. Symptoms that patients experience typically include a chronic cough, shortness of breath, chest pain, and coughing up blood. This condition typically develops due to cystic fibrosis.
Michael Moffat, co-founder and chief executive officer of Cavendish, said in a press release, “The theme of our Cleveland Clinic-hosted forum is a ‘Celebration of Philanthropy, Impact Investing and Innovation that Is Changing the World.’ With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence. The quality and originality of the Alitair Pharmaceuticals, Inc., approach to developing therapies for the orphan disease Bronchiectasis positions Alitair to make a major contribution to advancements in treatment for the 160,000 patients afflicted with this orphan disease in the U.S.”
“We are honored to have been selected to present at the upcoming Cavendish Global Health Impact Forum at the Cleveland Clinic,” said William W. Howard, Alitair’s president and CEO. “We welcome the chance to interact with many of world’s most accomplished scientists, thought-leaders and philanthropic individuals and families who share our dedication to improving the health and lives of people around the world.”
“Bronchiectasis is one of the country’s largest orphan diseases, and the annual medical costs for patients with Bronchiectasis are higher than many other chronic diseases, including heart disease and COPD,” added Howard. “We are eager to advance the development of two very promising compounds for the treatment of Bronchiectasis, Erdosteine and Doxofylline. We regard presenting at the Cavendish Global Impact Forum as an opportunity to inspire others to join us in our work to address the significant unmet need for effective and safe Bronchiectasis therapies.”
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?